TGM2 and brain cancer: It was further demonstrated that two tTG inhibitors, the irreversible peptidomimetic Z-Don and the alternate substrate MDC, decreased EGFR expression, and increased EGFR ubiquitination, when applied to U87 MG or LN229 brain cancer cells, and that knockdown of tTG had similar effects.